Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pancreatic cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: pancreatic cancer. Displaying page 11 of 26.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2014-003924-34 Sponsor Protocol Number: GETNE-1407 Start Date*: 2015-02-13
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos (GETNE)
    Full Title: A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET).
    Medical condition: Patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003181-40 Sponsor Protocol Number: 2012-249 Start Date*: 2012-12-11
    Sponsor Name:Foundation for Liverdisease
    Full Title: Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: a multicentre randomized phase III clinical trial
    Medical condition: patients with resectable or borderline resectable pancreatic cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004548-40 Sponsor Protocol Number: D17-01 Start Date*: 2018-11-08
    Sponsor Name:GERCOR
    Full Title: A randomized non-comparative phase II study of Maintenance therapy with OSE2101 vaccine alone or in combination with nivolumab, or FOLFIRI after induction therapy with FOLFIRINOX in patients with l...
    Medical condition: Locally advanced or metastatic Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-001126-24 Sponsor Protocol Number: AGO/GAS/04/01 Start Date*: 2004-10-25
    Sponsor Name:University Hospital Ghent
    Full Title: Feasibility of radiotherapy and concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma
    Medical condition: Pancreatic cancer or distal cholangiocarcinoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002574-36 Sponsor Protocol Number: PRODIGE35 Start Date*: 2014-08-20
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Phase II randomized study evaluation of FOLFIRINOX +/- LV5FU2 in maintenance and FIRGEM in 1rst line of metastatic pancreas cancer
    Medical condition: metastatic pancreas adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003866-15 Sponsor Protocol Number: ABI-007-PANC-CA046C Start Date*: 2014-01-24
    Sponsor Name:Celgene Corporation
    Full Title: MPACT EXTENSION STUDY: MULTICENTER, SURVIVAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN PROTOCOL CA046
    Medical condition: Metastatic Adenocarcinoma of the Pancreas
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004796-12 Sponsor Protocol Number: AIO-PAK-0113 Start Date*: 2014-07-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-004299-38 Sponsor Protocol Number: ESPAC-4Version:7Date:21/07/2011 Start Date*: 2008-09-17
    Sponsor Name:The University of Liverpool [...]
    1. The University of Liverpool
    2. The Royal Liverpool and Broadgreen University Hospital NHS Trust
    Full Title: European Study Group for Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers.
    Medical condition: Resectable pancreatic or peri-ampullary cancers
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    14.1 100000004864 10034446 Periampullary carcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Restarted) FI (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000293-20 Sponsor Protocol Number: INCB18424-362 Start Date*: 2014-07-31
    Sponsor Name:Incyte Corporation
    Full Title: INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of ...
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000974-18 Sponsor Protocol Number: AB07012 Start Date*: 2009-05-06
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabin...
    Medical condition: advanced/metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004068-13 Sponsor Protocol Number: HALO-109-301 Start Date*: 2016-03-02
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With P...
    Medical condition: Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) BE (Completed) GB (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002040-78 Sponsor Protocol Number: D8151C00001 Start Date*: 2021-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid...
    Medical condition: Pancreatic ductal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033599 Pancreatic adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002632-23 Sponsor Protocol Number: IFO21_02 Start Date*: 2021-12-22
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A proof-of-concept, biomarker-driven, phase-II clinical trial to explore the activity of decitabine repurposing against advanced, refractory, KRAS-dependent pancreatic ductal adenocarcinoma (PDAC):...
    Medical condition: Advanced (locally advanced or metastatic), pre-treated PDAC patients, progressing after at least one and no more than two lines of systemic therapy, whose tumors express a KRAS-dependency signature.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001080-36 Sponsor Protocol Number: 20150195 Start Date*: 2016-11-17
    Sponsor Name:Amgen Incorporated
    Full Title: A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
    Medical condition: Advanced Colorectal cancer (CRC), pancreatic cancer or non-small cell lung cancer (NSCLC), and other indications dependent on emerging data
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001247-64 Sponsor Protocol Number: CRAD001C2239 Start Date*: 2006-06-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy
    Medical condition: Advanced pancreatic neuroendocrine tumors (NET).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033630 Pancreatic islet cell neoplasm malignant NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001868-40 Sponsor Protocol Number: SIEGE Start Date*: 2013-11-05
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Scheduling nab-paclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nab-paclitaxel (Abraxane) combined with gemcitabine as first line treatment f...
    Medical condition: metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004231-23 Sponsor Protocol Number: 274948 Start Date*: 2020-05-29
    Sponsor Name:Queen Mary University of London
    Full Title: Phase IIb randomised clinical trial repurposing ATRA as a stromal targeting agent in a novel drug combination for pancreatic cancer
    Medical condition: Pancreatic cancer - locally advanced
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-004309-69 Sponsor Protocol Number: SPaCe-01 Start Date*: 2005-01-13
    Sponsor Name:GISCAD
    Full Title: A randomized phase II study of gemcitabine/cisplatin with or without Cetuximab to evaluate the efficacy in patients with locally advanced or metastatic EGFR-positive pancreatic cancer. SpaCe TRIAL.
    Medical condition: Locally advanced or metastatic EGFR-positive pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015674 HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003735-28 Sponsor Protocol Number: SONAZOID-PANCREAS-001 Start Date*: 2021-03-05
    Sponsor Name:Helse Bergen HF, Department of Medicine
    Full Title: The role of sonoporation-enhanced treatment with Gemcitabine, Nab-Paclitaxel and FOLFIRINOX in patients with inoperable pancreatic cancer.
    Medical condition: Histologically verified, locally advanced (nonresectable Stage II/III) or metastatic (Stage IV) adenocarcinoma of the pancreas.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000117-31 Sponsor Protocol Number: CAM-PLEX Start Date*: 2015-03-03
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor (Mozobil), at potentially active plasma concentrations and assess its impact on the immune microenvironment ...
    Medical condition: Pancreatic adenocarcinoma High grade serous ovarian adenocarcinoma Colorectal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 08 17:23:55 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA